AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Apr 07, 2026

A scalpel-free future for kidney tumors?

As histotripsy enters clinical trials, a needleless approach to RCC raises new possibilities—and new questions.


Abstract white mesh wave pattern flowing across dark blue background with smooth, undulating curves

Appropriately calibrating treatment intensity to underlying disease biology remains a challenge in renal cell carcinoma (RCC). This can lead to overtreatment of some renal masses that are unlikely to ever cause harm and undertreatment of patients who ultimately progress. 

Alexander Kutikov, MD, chair of the department of urology at the Fox Chase Cancer Center in Philadelphia and co-executive director of the Fox Chase Temple Urologic Institute, will discuss how focal therapy may address this challenge during the State-of-the-Art Lecture: The Emerging Role of Focal Therapy in Renal Cell Carcinoma at the 2026 AUA Annual Meeting. 

“Focal therapy bridges two main management strategies for small renal masses: active surveillance and surgery. In principle, it allows treatment of the tumor while exposing patients to less risk than surgical intervention,” Dr. Kutikov said.  Professional male healthcare provider in white lab coat and blue shirt smiling at cameraAlexander Kutikov, MD

However, focal therapy for RCC has its limitations. For example, current methods require percutaneous access and tissue puncture, making access to certain masses challenging, risky or impossible.  

A novel technology known as histotripsy is now emerging. Histotripsy uses focused ultrasound cavitation to achieve nonthermal, needleless tissue destruction. However, histotripsy remains unproven in kidney cancer and is appropriately confined to clinical trials. Its feasibility depends on anatomy and acoustic access, and its long-term oncologic performance remains unknown.  

“This is the nature of innovation. The ablation space is already crowded, the technology is expensive, and it remains unclear whether adoption will be driven primarily by urologists or interventional radiologists, factors that may influence its clinical traction,” said Dr. Kutikov.  

Clinical trials evaluating histotripsy for RCC are ongoing, and preliminary experience remains limited. Early feasibility studies are underway to determine safety, technical success and appropriate patient selection. 

While histotripsy is an exciting technology, it may face challenges to widespread adoption, given the platform's cost and the uncertain incremental benefit over existing ablation techniques. 

During the session, Dr. Kutikov will review the current role of focal therapy across the treatment spectrum for renal mass, including its relationship to active surveillance and surgery, the limitations of existing ablation modalities and the importance of matching treatment intensity to tumor biology. He will also discuss emerging technologies such as histotripsy. 

Dr. Kutikov said he hopes urologists will understand that focal therapy should not be viewed as a replacement for active surveillance or a substitute for surgery in patients with complex tumors that require surgical expertise. Rather, it may play a role in carefully selected patients for whom treatment is preferred, but the surgical risks are less appealing. 

Interesting Stories
Find your next big break at AUA2026
Sponsored by AUA
Find your next big break at AUA2026
Book your AUA2026 housing now
Sponsored by AUA
Book your AUA2026 housing now
Unique formulation of YONSA® (abiraterone acetate) makes it different
Sponsored by Sun Pharma
Unique formulation of YONSA® (abiraterone acetate) makes it different
AUA means business: AUA Annual Business Meeting is May 18
Sponsored by AUA
AUA means business: AUA Annual Business Meeting is May 18
More Content
Professional headshot of a man wearing glasses, pink shirt, and burgundy bow tie
Previews
Rethinking cancer detection
May 05, 2026
Pain scale gauge showing emotion faces ranging from happy green (no pain) to crying red (severe pain) with numbered indicator
Previews
The big shift
May 05, 2026
Professionals demonstrate robotic arm technology at hands-on event with participants wearing blue gloves
Previews
AUA2026 amps up hands-on skills training
May 05, 2026
Professional headshot of a man wearing glasses and business attire against a blue background
Previews
The great ablation debate
May 05, 2026
Glowing abstract sphere with horns and luminous network pattern on dark background
Previews
Bladder transplantation changes the game
Apr 21, 2026
Male surgeon in blue surgical cap and scrubs smiling at camera in hospital corridor
Previews
Scanning the best options
Apr 21, 2026
Professional headshot of a man in navy suit and striped tie with organizational pin
Previews
Separating myth from measurable outcomes
Apr 21, 2026
Illustration of a person working at a computer with robotic arms assembling digital technology above
Previews
AI: Your new interoperative partner
Apr 21, 2026
Surgical team performing minimally invasive procedure in operating room with imaging displays
Previews
Enhancing surgical vision
Apr 07, 2026
Professional headshot of a man wearing glasses, light blue shirt, and dark blazer with purple tie
Previews
To cut or not to cut? Bladder preservation takes center stage
Apr 07, 2026
Professional headshot of a man wearing glasses and business attire against a blue background
Previews
When BPH treatments fail
Apr 07, 2026
Medical team analyzing bladder anatomy and research data on digital screen
AUA2025
P2s spotlight groundbreaking clinical trials
Apr 15, 2025
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2026 Ascend Media. All rights reserved.